This observation raises the possibility that resistance to anti-angiogenic therapy may arise, at least in part, from the development of adaptive immune suppressive processes within tumors [95,111] and that antitumor efficacy of a simultaneous blockade could be further enhanced by anti-PD-1 treatment, in different tumor models [111]. Here, PDCD1 is linked to neoplasm.